Clinical Trial Detail

NCT ID NCT01972217
Title Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

prostate cancer

Therapies

Prednisone

Abiraterone

Olaparib

Age Groups: adult

No variant requirements are available.